Another anti-viral drug for the treatment of COVID-19 has been launched, this time by pharma major Cipla. To be sold in the market under the brand name of Cipremi, this one is a generic version of antiviral drug Remdesivir to be used in emergency treatment of COVID-19 patients.
This is the third drug to be approved in India for coronavirus treatment during the last few days, after Glenmark introduced Fabiflu and Hetero launched Covifor.
Cipla is yet to announce the pricing of Cipremi.
Remdesivir was last week included as part of “investigational therapy” in India by the Union Health Ministry. But the use was restricted to emergency situations only, as per the ministry’s clinical management protocol for COVID-19 patients.
The ministry also approved off-label application of immunomodulator tocilizumab and convalescent plasma therapy for treatment of coronavirus patients who are in moderate stage of criticality.
Remdesivir is the only USFDA-approved Emergency Use Authorisation (EUA) treatment for adults and children who are undergoing treatment in hospitals with suspected or laboratory-confirmed COVID-19 infection.